# Troriluzole, Trigriluzole **URL:** \ **Category:** General\ **Created:** [June 1, 2019, 9:45am UTC](https://forum.livingwithataxia.org/t/troriluzole-trigriluzole/7475 "2019-06-01T09:45:39Z")\ **Posts on this page:** 7\ **Page:** 1
**Author:** ![eunseo1](https://avatars.discourse-cdn.com/v4/letter/e/cc9497/32.png) [@eunseo1](https://forum.livingwithataxia.org/u/eunseo1)\ **Post date:** [June 1, 2019, 9:45am UTC](https://forum.livingwithataxia.org/t/troriluzole-trigriluzole/7475/1 "2019-06-01T09:45:39Z")
I want to hear recent news about the medication. I was told Dr. Parman at UCLA univ hospital is very positive of the drug! hoping to listen to the latest news. ---
**Author:** ![Shoaib](https://avatars.discourse-cdn.com/v4/letter/s/c5a1d2/32.png) [@Shoaib](https://forum.livingwithataxia.org/u/Shoaib)\ **Post date:** [June 1, 2019, 12:13pm UTC](https://forum.livingwithataxia.org/t/troriluzole-trigriluzole/7475/2 "2019-06-01T12:13:17Z")
I am on the 2nd. trial with Trigriluzole at Johns Hopkins. I am taking the original dose at 140mg. a day. There is a separate trial with 2 capsule (280mg) a day. Trigriluzole is a “Glutamate modulator” and takes up excess glutamate which is toxic to the nerves. Although, I have not seen a significant improvement, my neurologist thinks that my SARA score has not deteriorated during the study. Eventually, Trigriluzole may be approved by FDA for slowing down down the progression of the disease. But that’s a start. I hope more research will follow. ---
**Author:** ![eunseo1](https://avatars.discourse-cdn.com/v4/letter/e/cc9497/32.png) [@eunseo1](https://forum.livingwithataxia.org/u/eunseo1)\ **Post date:** [June 1, 2019, 12:59pm UTC](https://forum.livingwithataxia.org/t/troriluzole-trigriluzole/7475/3 "2019-06-01T12:59:16Z")
Thanks! we need a hope that there is no more degeneration. can’t wait till it get approved by FDA! ---
**Author:** ![eunseo1](https://avatars.discourse-cdn.com/v4/letter/e/cc9497/32.png) [@eunseo1](https://forum.livingwithataxia.org/u/eunseo1)\ **Post date:** [June 1, 2019, 1:15pm UTC](https://forum.livingwithataxia.org/t/troriluzole-trigriluzole/7475/4 "2019-06-01T13:15:51Z")
Thanks! we need a hope that there is no more degeneration. can’t wait till it gets approved by FDA! ---
**Author:** ![longbow06](https://yyz1.discourse-cdn.com/flex027/user_avatar/forum.livingwithataxia.org/longbow06/32/5503_2.png) [@longbow06](https://forum.livingwithataxia.org/u/longbow06)\ **Post date:** [August 31, 2024, 6:48pm UTC](https://forum.livingwithataxia.org/t/troriluzole-trigriluzole/7475/5 "2024-08-31T18:48:42Z")
does this pill any at all ? ---
**Author:** ![Beryl\_Park](https://yyz1.discourse-cdn.com/flex027/user_avatar/forum.livingwithataxia.org/beryl_park/32/5716_2.png) [@Beryl\_Park](https://forum.livingwithataxia.org/u/Beryl_Park)\ **Post date:** [September 2, 2024, 5:13pm UTC](https://forum.livingwithataxia.org/t/troriluzole-trigriluzole/7475/6 "2024-09-02T17:13:46Z")
This is current ‘news’ about Troriluzole. ‘Troriluzole, an experimental drug being developed by Biohaven, completed Phase 3 clinical trials last year. While the primary endpoint assessing benefit across all Spinocerebellar Ataxia (SCA) types was not met, Biohaven believes the results show benefit among participants with SCA Type 3 (SCA3)’. > **[NAF Calls on the FDA to Apply Regulatory Flexibility and Accept the NDA...](https://www.ataxia.org/naf-calls-on-the-fda-to-apply-regulatory-flexibility-and-accept-the-nda-filing-for-troriluzole/)** > > Submit your comments for the FDA by August 21st! ---
**Author:** ![Beryl\_Park](https://yyz1.discourse-cdn.com/flex027/user_avatar/forum.livingwithataxia.org/beryl_park/32/5716_2.png) [@Beryl\_Park](https://forum.livingwithataxia.org/u/Beryl_Park)\ **Post date:** [September 24, 2024, 10:13am UTC](https://forum.livingwithataxia.org/t/troriluzole-trigriluzole/7475/7 "2024-09-24T10:13:37Z")
- Biohaven plans to submit a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for troriluzole in the treatment of all SCA genotypes in 4Q 2024. The application is eligible for a priority review given orphan drug and fast-track designations previously granted by FDA. > **[Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in...](https://www.prnewswire.com/news-releases/biohaven-achieves-positive-topline-results-in-pivotal-study-of-troriluzole-in-spinocerebellar-ataxia-sca-302255056.html?fbclid)** > > Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale...